Tolerability of indacaterol, a novel once-daily β2-agonist, in patients with asthma: A randomized, placebo-controlled, 28-day safety study

Annals of Allergy, Asthma and Immunology

Volumn 99, Issue 6, 2007, Pages 555-561

  Yang, William H ^a   Martinot, Jean Benoit ^b   Pohunek, Petr ^c   Beier, Jutta ^d   Magula, Daniel ^e   Cameron, Ray ^f   Owen, Roger ^f   Higgins, Mark ^f  

^a Allergy and Asthma Research Centre   (Canada)

^b Clinique & Maternite Sainte Elisabeth Namer   (Belgium)

^c CHARLES UNIVERSITY   (Czech Republic)

^d Institut fur Atemwegsforschung INSAF   (Germany)

^e Specialized Hospital of St Zoerardus Zobor   (Slovakia)

^f NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; GLUCOSE; INDACATEROL; LEUKOTRIENE RECEPTOR BLOCKING AGENT; PLACEBO; POTASSIUM;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; BRONCHOSPASM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEMOGRAPHY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERVENTILATION; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POTASSIUM BLOOD LEVEL; POWDER INHALER; PRIORITY JOURNAL; PULSE RATE; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHOOL CHILD; SKIN MANIFESTATION; STATISTICAL ANALYSIS; TREMOR; WHEEZING;

EID: 37349020090     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60386-9     Document Type: Article

References (20)

1. Crane J, Burgess C, Beasley R. Cardiovascular and hypokalaemic effects of inhaled salbutamol, fenoterol and isoprenaline. Thorax. 1989;44:136-140.
2. Maconochie JG, Forster JK. Dose-response study with high-dose inhaled salmeterol in healthy subjects. Br J Clin Pharmacol. 1992;33:342-345.
3. Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE. Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol and terbutaline in asthma. Lancet. 1990; 336:1396-1399.
4. Lipworth BJ, Clark RA, Fraser CG, McDevitt DG. The biochemical effects of high-dose inhaled salbutamol in patients with asthma. Eur J Clin Pharmacol. 1989;36:357-360.
5. 2-agonist, provides sustained 24-h bronchodilation in asthma. Eur Respir J. 2007;29:871-878.
6. 2-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial [published online ahead of print September 30, 2006]. Pulm Pharmacol Ther. doi:10.1016/j.pupt.2006.09.001.
7. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows: Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal: Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993;16:5-40.
8. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296-1310.
9. Venables TL, Addlestone MB, Smithers AJ, et al; PROOF Research Group. A comparison of the efficacy and patient acceptability of once daily budesonide via turbohaler and twice daily fluticasone propionate via disc-inhaler at an equal daily dose of 400 μg in adult asthmatics. Br J Clin Res. 1996;7:15-32.
10. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990;150:1881-1884.
11. 2- adrenoceptor agonists in asthma management. Respir Med. 2005;99:152-170.
12. Moratinos J, Reverte M. Effects of catecholamines on plasma potassium: the role of α- and β-adrenoceptors. Fundam Clin Pharmacol. 1993;7:143-153.
13. Sears MR. Adverse effects of β-agonists. J Allergy Clin Immunol. 2002;110:S322-S328.
14. Maconochie JG, Minton NA, Chilton JE, Keene ON. Does tachyphylaxis occur to the non-pulmonary effects of salmeterol? Br J Clin Pharmacol. 1994;37:199-204.
15. 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients. Thorax. 1995;50:497-504.
16. Dogan A, Tunc E, Varol E, Ozaydin M, Ozturk M. Comparison of the four formulas of adjusting QT interval for the heart rate in the middle-aged healthy Turkish men. Ann Noninvasive Electrocardiol. 2005;10:134-141.
17. Chuchalin AG, Tsoi AN, Richter K, et al. Safety and tolerability of indacaterol in asthma: a randomized, placebo-controlled 28-day study [published online ahead of print July 19, 2007]. Respir Med. doi:10.1016/j.rmed. 2007.06.002.
18. 2-agonist, is well tolerated in patients with mild asthma [abstract P1727]. Eur Respir J. 2005;26(suppl 49):253s.
19. 2-agonist, demonstrates 24-hour efficacy and is well tolerated in patients with asthma: a multiple-dose, dose-ranging study [abstract P1729]. Eur Respir J. 2005;26(suppl 49):253s.
20. 2-agonist, is effective and well tolerated in multiple dosing in patients with mild to moderate COPD [abstract P1920]. Eur Respir J. 2005;26(suppl 49):287s.